Bacterial conjunctivitis

Summary

Bacterial conjunctivitis (MONDO:0006668) is a disease and 31 clinical trials. Top therapeutic interventions include moxifloxacin, besifloxacin, and gatifloxacin. A subtype of conjunctivitis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 31

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	bacterial conjunctivitis
Mondo ID	MONDO:0006668
EFO	EFO:1000829
MeSH	D003234
DOID	DOID:9700
ICD-11	902481358
NCIT	C53656
SNOMED CT	243321006
UMLS	C0009768
MedGen	3209
MedDRA	10061784
Is cancer (heuristic)	no

Also known as: Bacteria caused conjunctival disease · Bacteria conjunctival disease

Disease family

This is a subtype of conjunctivitis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › disorder of orbital region › eye adnexa disorder › conjunctival disorder › conjunctivitis › bacterial conjunctivitis

Related subtypes (7): acute conjunctivitis, blepharoconjunctivitis, papillary conjunctivitis, chronic conjunctivitis, keratoconjunctivitis, rosacea conjunctivitis, viral conjunctivitis

Subtypes (3): pseudomembranous conjunctivitis, inclusion conjunctivitis, gonococcal conjunctivitis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

2 approved, 6 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Azithromycin	Approved (phase 4)
Gatifloxacin	Approved (phase 4)
Besifloxacin	Phase 3 (in late-stage trials)
Moxifloxacin	Phase 3 (in late-stage trials)
Ofloxacin	Phase 3 (in late-stage trials)
Pazufloxacin	Phase 3 (in late-stage trials)
Tobramycin	Phase 3 (in late-stage trials)
Vancomycin	Phase 3 (in late-stage trials)

Clinical trials & evidence

Clinical trials

Clinical trials: 31.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE3	18
PHASE2	5
PHASE4	3
PHASE2/PHASE3	2
PHASE1	2
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00312338	PHASE4	COMPLETED	Topical Treatment of Bacterial Conjunctivitis and Its Effect on Microbial Flora
NCT00464438	PHASE4	COMPLETED	A Study to Evaluate the Safety and Efficacy of Gatifloxacin for the Treatment of Bacterial Conjunctivitis
NCT00798577	PHASE4	COMPLETED	Study of the Progression of Bacterial Conjunctivitis Symptoms Upon Antibiotic Treatment
NCT06911424	PHASE3	RECRUITING	Efficacy of Fusidic Acid 1% in the Treatment of Bacterial Conjunctivitis
NCT00105469	PHASE3	COMPLETED	Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Tobramycin for Bacterial Conjunctivitis (C-01-401-004)
NCT00105534	PHASE3	COMPLETED	Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Vehicle for Bacterial Conjunctivitis (C-01-401-003)
NCT00331916	PHASE3	COMPLETED	AL-15469A for the Treatment of Bacterial Conjunctivitis
NCT00332293	PHASE3	COMPLETED	AL-15469A for the Treatment of Bacterial Conjunctivitis
NCT00347932	PHASE3	COMPLETED	A Study to Determine if 0.6% ISV-403 is Safe and Effective in the Treatment of Bacterial Conjunctivitis.
NCT00348348	PHASE3	COMPLETED	A Study to Investigate the Safety and Efficacy of BOL-303224 in the Treatment of Bacterial Conjunctivitis
NCT00509873	PHASE3	COMPLETED	A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis
NCT00518089	PHASE3	COMPLETED	A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis
NCT00565123	PHASE2/PHASE3	COMPLETED	Study of Efficacy of Levofloxacin 0.5% Ophthalmic Solution Administered Three Times a Day for Bacterial Conjunctivitis
NCT00759148	PHASE3	COMPLETED	Moxifloxacin AF Ophthalmic Solution for Treatment of Bacterial Conjunctivitis
NCT00972777	PHASE2/PHASE3	COMPLETED	Efficacy of Besifloxacin Ophthalmic Suspension in the Treatment of Bacterial Conjunctivitis
NCT01175590	PHASE3	COMPLETED	Safety of Besivance™ (Besifloxacin Ophthalmic Suspension) 0.6% Compared to Vehicle
NCT01227863	PHASE3	UNKNOWN	Efficacy Maxinom® And Maxitrol® in Reducing The Signs And Symptoms Of Acute Bacterial Conjunctivitis
NCT01227915	PHASE3	UNKNOWN	Effectiveness Comparison Between the Drugs TOBRACORT® and TOBRADEX® in Reducing the Signs and Symptoms of Acute Bacterial Conjunctivitis
NCT01330355	PHASE3	TERMINATED	Besifloxacin Ophthalmic Suspension Verses Gatifloxacin Ophthalmic Solution in Neonates With Bacterial Conjunctivitis
NCT01573910	PHASE3	COMPLETED	An Evaluation of the Safety and Efficacy of Moxifloxacin Ophthalmic Solution 0.5% ((VIGAMOX®) Versus Ofloxacin Ophthalmic Solution 0.3% in the Treatment of Bacterial Conjunctivitis in Chinese Patients
NCT01740388	PHASE3	TERMINATED	Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% in the Treatment of Bacterial Conjunctivitis
NCT02432807	PHASE3	COMPLETED	Safety and Efficacy of Vancomycin Ophthalmic Ointment in Patients With Moderate to Severe Bacterial Conjunctivitis
NCT03004924	PHASE3	COMPLETED	Treatment of Bacterial Conjunctivitis With SHP640 Compared to PVP-Iodine and Placebo
NCT07565103	PHASE1/PHASE2	NOT_YET_RECRUITING	Safety and Efficacy of SUM-191 for Patients With Bacterial Conjunctivitis
NCT00622908	PHASE2	COMPLETED	Clinical and Microbial Efficacy of ISV403 in Bacterial Conjunctivitis
NCT01238783	PHASE2	WITHDRAWN	Safety and Efficacy of AL-15469A 0.5% / AL-6515 0.3% Ophthalmic Suspension for Treatment of Bacterial Conjunctivitis
NCT01877694	PHASE2	COMPLETED	Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial Conjunctivitis
NCT02980523	PHASE2	COMPLETED	Safety and Efficacy of PRO-157 vs Moxifloxacin vs Gatifloxacin in Patients With Bacterial Conjunctivitis (Pazufloxacin)
NCT05816070	PHASE2	COMPLETED	Trial to Evaluate the Efficacy and Safety of IVIEW-1201 in Acute Bacterial Conjunctivitis
NCT03235141	PHASE1	UNKNOWN	Local Pharmacokinetics of Azithromycin Eye Drops in Healthy Volunteers
NCT06363292	PHASE1	COMPLETED	Study to Evaluate the Safety and Tolerability of PRO-231 Versus VIGAMOXI® on the Ocular Surface of Healthy Subjects

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
MOXIFLOXACIN	4	9
BESIFLOXACIN	4	7
GATIFLOXACIN	4	4
FUSIDIC ACID	4	1
NEPAFENAC	4	1
TOBRAMYCIN	4	1
AURICLOSENE	2	1
VEHICLE	0	4
CHEMBL134350	0	1